$RGLS
Regulus Therapeutics Inc. Stock $rgls

$rgls Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-Q Financial Statement

#000162828020007809 Filed on May 14, 2020

Income Statement

Concept	2020 Q1	2019 Q1
Revenue	$6.000K	$6.778M
YoY Change	-99.91%	37555.56%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.420M	$3.530M
YoY Change	-31.44%	-6.37%
% of Gross Profit
Research & Development	$3.119M	$5.983M
YoY Change	-47.87%	-49.42%
% of Gross Profit
Depreciation & Amortization	$126.0K	$502.0K
YoY Change	-74.9%	-10.83%
% of Gross Profit
Operating Expenses	$5.541M	$9.516M
YoY Change	-41.77%	-39.0%
Operating Profit	-$5.535M	-$2.738M
YoY Change	102.15%	-82.43%
Interest Expense	$489.0K	$578.0K
YoY Change	-15.4%	-4.46%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$5.945M	-$3.260M
YoY Change	82.36%	-79.66%
Income Tax	-$8.000K	$0.00
% Of Pretax Income
Net Earnings	-$5.937M	-$3.260M
YoY Change	82.12%	-79.66%
Net Earnings / Revenue	-98950.0%	-48.1%
Basic Earnings Per Share
Diluted Earnings Per Share	-$246.9K	-$314.1K
COMMON SHARES
Basic Shares Outstanding	21.04M shares	10.74M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q1	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$28.10M	$10.30M
YoY Change	172.82%	-77.16%
Cash & Equivalents	$28.05M	$10.32M
Short-Term Investments
Other Short-Term Assets	$955.0K	$801.0K
YoY Change	19.23%	-44.8%
Inventory
Prepaid Expenses	$3.924M	$3.826M
Receivables	$700.0K	$2.800M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$33.61M	$17.74M
YoY Change	89.45%	-65.51%
LONG-TERM ASSETS
Property, Plant & Equipment	$801.0K	$1.598M
YoY Change	-49.87%	-82.83%
Goodwill
YoY Change
Intangibles	$159.0K	$407.0K
YoY Change	-60.93%	-43.94%
Long-Term Investments
YoY Change
Other Assets	$439.0K	$133.0K
YoY Change	230.08%	-78.55%
Total Long-Term Assets	$1.399M	$2.138M
YoY Change	-34.57%	-79.93%
TOTAL ASSETS
Total Short-Term Assets	$33.61M	$17.74M
Total Long-Term Assets	$1.399M	$2.138M
Total Assets	$35.01M	$19.88M
YoY Change	76.11%	-67.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.030M	$2.650M
YoY Change	-61.13%	-39.72%
Accrued Expenses	$860.0K	$1.745M
YoY Change	-50.72%	-48.23%
Deferred Revenue	$0.00	$60.00K
YoY Change	-100.0%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$14.60M	$15.50M
YoY Change	-5.81%	-22.11%
Total Short-Term Liabilities	$19.79M	$24.84M
YoY Change	-20.35%	-19.7%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$200.0K
YoY Change	-100.0%
Other Long-Term Liabilities	$318.0K	$1.106M
YoY Change	-71.25%	152.51%
Total Long-Term Liabilities	$318.0K	$1.106M
YoY Change	-71.25%	152.51%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.79M	$24.84M
Total Long-Term Liabilities	$318.0K	$1.106M
Total Liabilities	$20.10M	$25.95M
YoY Change	-22.52%	-33.82%
SHAREHOLDERS EQUITY
Retained Earnings	-$417.3M	-$396.0M
YoY Change	5.37%	15.11%
Common Stock	$432.2M	$389.9M
YoY Change	10.83%	1.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$14.90M	-$6.069M
YoY Change
Total Liabilities & Shareholders Equity	$35.01M	$19.88M
YoY Change	76.11%	-67.98%

Cashflow Statement

Concept	2020 Q1	2019 Q1
OPERATING ACTIVITIES
Net Income	-$5.937M	-$3.260M
YoY Change	82.12%	-79.66%
Depreciation, Depletion And Amortization	$126.0K	$502.0K
YoY Change	-74.9%	-10.83%
Cash From Operating Activities	-$6.002M	-$4.433M
YoY Change	35.39%	-71.59%
INVESTING ACTIVITIES
Capital Expenditures	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$160.0K
YoY Change	-100.0%	-98.6%
Cash From Investing Activities	$0.00	$161.0K
YoY Change	-100.0%	-98.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$1.000K	$2.086M
YoY Change	-99.95%	902.88%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$67.00K	$657.0K
YoY Change	-110.2%	-6.28%
NET CHANGE
Cash From Operating Activities	-$6.002M	-$4.433M
Cash From Investing Activities	$0.00	$161.0K
Cash From Financing Activities	-$67.00K	$657.0K
Net Change In Cash	-$6.069M	-$3.615M
YoY Change	67.88%	4.42%
FREE CASH FLOW
Cash From Operating Activities	-$6.002M	-$4.433M
Capital Expenditures	$0.00
Free Cash Flow	-$6.002M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-57000	USD
CY2019Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2518000	USD
CY2020Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-6000	USD
CY2019Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	314000	USD
CY2020Q1	dei	Amendment Flag AmendmentFlag	false
CY2019	rgls	Noncash Leasehold Improvements NoncashLeaseholdImprovements	5600000	USD
CY2019Q1	rgls	Paymentson Finance Leases PaymentsonFinanceLeases	65000	USD
CY2020Q1	rgls	Paymentson Finance Leases PaymentsonFinanceLeases	68000	USD
CY2019Q1	rgls	Proceeds Paymentsfrom Saleand Acquisitionof Property Plantand Equipment Net ProceedsPaymentsfromSaleandAcquisitionofPropertyPlantandEquipmentNet	161000	USD
CY2020Q1	rgls	Proceeds Paymentsfrom Saleand Acquisitionof Property Plantand Equipment Net ProceedsPaymentsfromSaleandAcquisitionofPropertyPlantandEquipmentNet	0	USD
CY2019	rgls	Noncash Gain Dueto Reductionof Lease Liability NoncashGainDuetoReductionofLeaseLiability	1300000	USD
CY2020Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q1	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
CY2020Q1	dei	Document Type DocumentType	10-Q
CY2020Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001505512
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27608783	shares
CY2020Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q1	dei	Entity Number Of Employees EntityNumberOfEmployees	21	employee
CY2020Q1	dei	Entity Registrant Name EntityRegistrantName	REGULUS THERAPEUTICS INC.
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2019Q1	rgls	Gainon Reductionof Lease Liability GainonReductionofLeaseLiability	1317000	USD
CY2020Q1	rgls	Gainon Reductionof Lease Liability GainonReductionofLeaseLiability	0	USD
CY2019Q1	rgls	Lease Payments Eliminated LeasePaymentsEliminated	14400000	USD
CY2016Q4	rgls	Tenant Improvement Allowance TenantImprovementAllowance	8200000	USD
CY2020Q1	rgls	Warrants Exercised WarrantsExercised	0	shares
CY2019Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	1141000	USD
CY2020Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	676000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1321000	USD
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1030000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	917000	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	860000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	431305000	USD
CY2020Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	432129000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	959000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	823000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	959000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	823000	USD
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1180337	shares
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	36680830	shares
CY2019Q4	us-gaap	Assets Assets	42081000	USD
CY2020Q1	us-gaap	Assets Assets	35006000	USD
CY2015Q3	us-gaap	Incentive From Lessor IncentiveFromLessor	1400000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3260000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	21000	USD
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	22000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6000	USD
CY2020Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	24388000	USD
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21018663	shares
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27608783	shares
CY2019Q4	us-gaap	Assets Current AssetsCurrent	40407000	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	33607000	USD
CY2019Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	8909000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34121000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28052000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13935000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10320000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34121000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28052000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3615000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6069000	USD
CY2020Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	85216000	shares
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21018663	shares
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27608783	shares
CY2020Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	USD
CY2019Q4	us-gaap	Debt Current DebtCurrent	14631000	USD
CY2020Q1	us-gaap	Debt Current DebtCurrent	14636000	USD
CY2019Q4	us-gaap	Deferred Costs Leasing Accumulated Amortization DeferredCostsLeasingAccumulatedAmortization	900000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	502000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	126000	USD
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.31
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1676000	USD
CY2020Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	532000	USD
CY2020Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	265000	USD
CY2020Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	265000	USD
CY2020Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	USD
CY2020Q1	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	272000	USD
CY2020Q1	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	57000	USD
CY2020Q1	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	215000	USD
CY2020Q1	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	7000	USD
CY2019	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	-1600000	USD
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3533000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2422000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1076000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-400000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	42081000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5945000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35006000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	765000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-8000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	2766000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-466000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	936000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-291000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	120000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	442000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	323000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	72000	USD
CY2015Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P96M
CY2020Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1144000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-532000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-313000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	22066000	USD
CY2020Q1	us-gaap	Liabilities Liabilities	20104000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-368000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	0	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	266000	USD
CY2020Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	159000	USD
CY2019Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	56000	USD
CY2020Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	79000	USD
CY2019Q1	us-gaap	Interest Expense InterestExpense	578000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	489000	USD
CY2019Q1	us-gaap	Interest Paid Net InterestPaidNet	437000	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	384000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21598000	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	19786000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	657000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-67000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	161000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4433000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6002000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-3260000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-5937000	USD
CY2015Q3	us-gaap	Net Rentable Area NetRentableArea	59248	sqft
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	9516000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	5541000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2738000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5535000	USD
CY2020Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	693000	USD
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	375000	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	318000	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1221000	USD
CY2020Q1	us-gaap	Other Assets Current OtherAssetsCurrent	955000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	487000	USD
CY2020Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	439000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3047000	USD
CY2020Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2728000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	468000	USD
CY2020Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	318000	USD
CY2019Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	139000	USD
CY2020Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	105000	USD
CY2019Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3924000	USD
CY2020Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3924000	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2086000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	921000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	801000	USD
CY2019Q1	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	1364000	USD
CY2020Q1	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	0	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5983000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3119000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-411315000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-417252000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6778000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	959000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	823000	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6116000	shares
CY2019Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2084000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-5854000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	-6069000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	20015000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	14902000	USD
CY2018Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0833
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10379830	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24064373	shares
CY2020Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our condensed financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions. Though the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty, we continue to use the best information available to inform our critical accounting estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-20-007809-index-headers.html	Edgar Link	pending
0001628280-20-007809-index.html	Edgar Link	pending
0001628280-20-007809.txt	Edgar Link	pending
0001628280-20-007809-xbrl.zip	Edgar Link	pending
ex-101x20200331.htm	Edgar Link	pending
ex-311x20200331.htm	Edgar Link	pending
ex-312x20200331.htm	Edgar Link	pending
ex-321x20200331.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rgls-20200331.xml	Edgar Link	completed
rgls-20200331.xsd	Edgar Link	pending
rgls-20200331_cal.xml	Edgar Link	unprocessable
rgls-20200331_def.xml	Edgar Link	unprocessable
rgls-20200331_lab.xml	Edgar Link	unprocessable
rgls-20200331_pre.xml	Edgar Link	unprocessable
rgls20200331-10q.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RGLS
Regulus Therapeutics Inc. Stock $rgls

2020 Q1 Form 10-Q Financial Statement

#000162828020007809 Filed on May 14, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGLS Regulus Therapeutics Inc. Stock $rgls

2020 Q1 Form 10-Q Financial Statement

#000162828020007809 Filed on May 14, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGLS
Regulus Therapeutics Inc. Stock $rgls